On July 2, 2025, the FDA granted accelerated approval to Zegfrovy (sunvozertinib) for people facing locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion […]
On July 2, 2025, the FDA granted accelerated approval to Zegfrovy (sunvozertinib) for people facing locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion […]